The drug Selinexor blocks specific protein that has been shown to be overexpressed in many types of cancer. Authors in this study evaluated the tolerability and the safety of this drug in Asian patients with advanced cancer and metastatic malignancies. Findings identified the recommended dose that can be used for future Selinexor monotherapy and drug combination studies for Asian patients.
Read more: https://journals.sagepub.com/doi/full/10.1177/17588359221087555
